Parakkal Deepak MBBS, MS, FACG
About
Parakkal Deepak, MBBS, MS, FACG is currently a physician-scientist in the Inflammatory Bowel Disease (IBD) Center in the Division of Gastroenterology at the Washington University School of Medicine (WUSM) in St. Louis, Missouri where he is a Professor of Medicine, Co-Director of the IBD center and Director of Clinical and Translation research for the Division of Gastroenterology. He is a Fellow of ACG and has been recognized as a ‘AGA Future Leader’ by the American Gastroenterological Association. He also serves as the Deputy Director of Data Quality and Enhancement of the prospective longitudinal biobanking cohort, the SPARC-IBD of the Crohn’s and Colitis Foundation.
His work in perianal Crohn’s disease has been funded by the American Gastroenterological Association, the Leona M. and Harry B. Helmsley Charitable Trust and the Litwin grant of the Crohn’s and Colitis Foundation, apart from investigator-initiated grants funded by industry and philanthropic funding from Leo & Carean Goss Crohn’s Disease Research Fund . His group’s primary focus is on fistulizing perianal Crohn’s disease where he co-leads a bench-bedside basic-translational-clinical group focused on improving the precision of care in perianal CD through single cell RNAseq and spatial transcriptomics, radiomics from fistula MRI pelvis, standard PET MR/novel tracers and 3D print applications and is part of the international TOpCLASS fistula consortium. The radiomics work is funded by Helmsley Trust. Additional focus area in research is cardiometabolic syndrome in IBD where his group has made novel observations in prevalence of NAFLD, risk of cirrhosis, performance of current ASCVD prediction tools and is investigating the impact of GLP1RAs in patients with IBD through a prospective study funded by Helmsley Trust. He is also investigating imaging of inflammation and fibrosis in small bowel CD through novel PET tracers to CCR2 and FAPI. He has co-founded the REBOOT IBD consortium across 11 leading IBD centers in the United States to publish real-world data on outcomes with newest advanced therapies in IBD. He also serves as section councilor for the Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) section of the AGA Institute Council.
Related Articles & Publications
Related Research Groups
